Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

BACKGROUND: Molecular mechanisms driving acquired resistance to anti-EGFR therapies in metastatic colorectal cancer (mCRC) are complex but generally involve the activation of the downstream RAS-RAF-MEK-MAPK pathway. Nevertheless, even if inhibition of EGFR and MEK could be a strategy for overcoming...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Exp Clin Cancer Res
Päätekijät: Napolitano, S., Matrone, N., Muddassir, A. L., Martini, G., Sorokin, A., De Falco, V., Giunta, E. F., Ciardiello, D., Martinelli, E., Belli, V., Furia, M., Kopetz, S., Morgillo, F., Ciardiello, F., Troiani, T.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2019
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6915948/
https://ncbi.nlm.nih.gov/pubmed/31842958
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1497-0
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia